Gender and cutaneous melanoma

British Journal of Dermatology

Volumn 136, Issue 5, 1997, Pages 657-665

  Miller, J G ^a   Mac Neil, S ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; SEX HORMONE; STEROID RECEPTOR; TAMOXIFEN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; FEMALE; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; TUMOR GROWTH;

EID: 8544279576     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03648.x     Document Type: Review

References (58)

1. Magnus K. Prognosis in malignant melanoma of the skin: significance of stage of disease, anatomical site, sex, age and period of diagnosis.. Cancer 1977: 40: 389-97.
2. Shaw HM, McGovern VJ, Milton GW et al. Histologic features of tumours and the female superiority in survival from malignant melanoma.. Cancer 1980: 45: 1604-8.
3. Shaw HM, McGovern VJ, Milton GW et al. Malignant melanoma: influence of site of lesion and age ol patient in the female superiority in survival.. Cancer 1980: 46: 2731-5.
4. Mackie RM, Watt D, Doherty V, Aitchison T. Malignant melanoma occurring in those aged under 30 in the West of Scotland 1979-1986: a study of incidence, clinical features, pathological features and survival.. Br J Dermatol 1991: 124: 560-4.
5. Cascinelli N, Morabito A, Bufalino R et al. Prognosis of stage I melanoma of the skin. Int J Cancer 1980: 26: 733-9.
6. Reintgen DS, Paull DE, Seigler HF et al. Sex related survival differences in instances of melanoma. Surg Gynecol Obstet 1984: 159: 367-72.
7. O'Doherty CJ, Prescott RJ, While H et al. Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease.. Cancer 1986: 58: 788-92.
8. Vossaert KA, Silverman MK, Kopf AW et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992: 26: 429-40.
9. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993: 71: 2995-3005.
10. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 1994: 129: 316-24.
11. Karakousis CP, Driscoll DL. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer 1995: 31A: 320-4.
12. Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995: 75: 2484-91.
13. Rampen FHJ, Mulder JH. Malignant melanoma: an androgen-dependent tumour?. Lancet 1980: i: 562-4.
14. Rampen FHJ. Sex differences in survival from cutaneous melanoma. Int J Dermatol 1984: 23: 444-52.
15. Eldh J, Boery B, Peterson L-E. Prognostic factors in cutaneous malignant melanoma in stage I. A clinical, morphological and multivariate analysis. Scand J Plast Reconstr Surg 1978: 12: 243-55.
16. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanoma: a regression-model analysis based on nationwide cancer registry data. Cancer 1988: 62: 2274-80.
17. Blois MS, Sagebiel RW, Abarbanel RM et al. Malignant melanoma of the skin 1. The association of tumor depth and type, and patient sex, age and site with survival. Cancer 1983: 52: 1330-41.
18. Johnson OK, Emrich LJ, Karakousis CP et al. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical stage I. Cancer 1985: 55: 1107-17.
19. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992: 327: 516-23.
20. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994: 343: 913-14.
21. Feucht KA, Walker MJ, Das Gupta TK, Beattie CW. Effect of 17β-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res 1988; 48 (24 Pt 1): 7093-101.
22. Ladanyi A, Timar J, Bocsi J et al. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res 1995; 5: 83-6.
23. Dewhurst LO, Gee JW, Rennie IG, Mac Neil S, Tamoxifen. 17β-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer 1997 (in press).
24. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage 1. 3. The relation between tumour-associated lymphocytic infiltration and age, sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Stand [A]. 1978: 86: 523.
25. Hodgins MB. Steroid hormones, receptors and malignant melanoma. Pigment Cell 1983: 6: 116-26.
26. McLeod SD, Ranson M, Mason RS. Effects of estrogens on human melanocytes. in vitro. J Steroid Biochem Mol Biol 1994: 49(1): 9-14.
27. Jee SH, Lee SY, Chiu HC et al. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun 1994: 199: 1407-12.
28. Flowers JL, Seigler HF, McCarty KS Sr et al. Absence of estrogen receptor in human melanomas as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 1987: 123: 764-5.
29. Cohen C, DeRose PB, Campbell WG, et al. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 1990: 12: 562-4.
30. Duncan LM, Travers RL, Koerner FC et al. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically delectable hormone receptors. Hum Pathol 1994: 25: 36-41.
31. Piantelli M, Maggiano N, Ricci R et al. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 1995: 105: 248-53.
32. Walker MJ, Beattie CW, Patel MK et al. Estrogen receptor in malignant melanoma. J Clin Oncol 1987: 5: 1256-61.
33. Clark JH, Hardin JM, Upchurch S, Eriksson H. Heterogeneity of estrogen binding sites in the cytosol of the rat uterus. J Biol Chem 1978: 253: 7630-4.
34. Ferrandina G, Scambia G, Panici PB et al. Type II estrogen-binding sites in human ovarian cancer: correlation with estrogen, progesterone, and epidermal growth factor receptor. Gynaecol Oncol 1993: 49: 67-72.
35. Markaverich BM, Upchurch S, Clark JH. Effects of salt extraction on the quantification of nuclear oestrogen receptors: Interference by secondary oestrogen binding sites. J Receptor Res 1980: 1: 415-38.
36. Jatoi I, Gore ME. Sex, pregnancy, hormones, and melanoma. Br Med J 1993: 307; 2-3.
37. Slingluff CL, Reintgen D. Malignant melanoma and the prognostic implications of pregnancy, oral contraceptives, and exogenous hormones. Semin Surg Oncol 1993: 9: 228-31.
38. Lederman JS, Lew RA, Koh HK, Sober AJ. Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J natl Cancer Inst 1985: 74: 981-5.
39. Rumke P, Kleeberg UR, MacKie RM et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res 1992: 2: 153-6.
40. McClay EF, McClay ME. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma.? J Clin Oncol 1994: 12: 617-26.
41. Rusthoven JJ. Quirt IC, Iscoe NA et al. Randomised, double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbasine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996: 14: 2083-90.
42. Mac Neil S, Wagner M, Kirkham PR et al. Inhibition of melanoma cell/ matrix interaction by tamoxifen. Melanoma Res 1993: 3: 67-74.
43. Mac Neil S, Wagner M, Rennie IG. Investigation of the role of signal transduction in attachment of ocular melanoma cells to matrix proteins: inhibition of attachment by calmodulin antagonists including tamoxifen. Tamoxifen. Clin Exp Metastasis 1994: 12(6): 375-84.
44. Mac Neil S, Wagner M, Rennie IG. Tamoxifen inhibition of ocular melanoma cell attachment to matrix proteins. Pigment Cell Res 1994: 7: 222-6.
45. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979: 86: 343-51.
46. Balch CM, Soong S-J, Milton GW et al. A comparison of prognostic factors and surgical results in 1,786 patients with localised (stage I) melanoma treated in Alabama. USA. and New South Wales, Australia. Ann Surg 1982: 196: 677-83.
47. Drzewiecki KT, Andersen PK. Survival with malignant melanoma. A regression analysis of prognostic factors. Cancer 1982: 49: 2414-19.
48. Hacene K, Le Doussal V, Brunet M et al. Prognostic index for clinical stage I cutaneous malignant melanoma. Cancer Res 1983: 43:2991-6.
49. Cascinelli N, Vaglini M, Bufalino R, Morabito A. BANS A cutaneous region with no prognostic significance in patients with melanoma. Cancer 1986: 57: 441-4.
50. Meyskens FL, Berdeaux DH, Parks B et al. Cutaneous malignant melanoma (Arizona Cancer Center experience) I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer 1988: 62: 1207-14.
51. Ringborg U, Afzelius L-E, Lagerlof B et al. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer 1995: 71: 751-8.
52. Creagan ET, Ingle JN, Woods JE et al. Estrogen receptors in patients with malignant melanoma. Cancer 1980: 57: 1785-6.
53. Kokoschka E-M, Spona J, Knobler R. Sex steroid hormones receptor analysis in malignant melanoma. Br J Dermatol 1982: 107 (Suppl. 23): 54-9.
54. Ellis DC, Wheeland RG, Solomon H. Estrogen and progesterone receptors in primary cutaneous melanoma. J Dermatol Surg Oncol 1985: 11: 54-9.
55. Delarue J-C, Avril M-F, Charpentier P, Prade M. Estrogen receptors in malignant melanoma. Arch Dermatol 1987: 123: 159-60.
56. Forno M, Borg A, Ingvar C, Jonsson PE. Estrogen receptor and binding site for estramustine in metastatic malignant melanoma. Anticancer Res 1987: 7(4B): 741-3.
57. Lecavalier MA, From L, Gaid N. Absence of estrogen receptors in dysplastic naevi and malignant melanoma. J Am Acad Dermatol 1990: 23: 242-6.
58. Walker MJ, Ronan SG, Han MC et al. Interrelationship between histopathologic characteristics of melanoma and estrogen receptor status. Cancer 1991: 68: 184-8.